Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04751396 · ClinicalTrials.gov registry record
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
A clinical trial of Melanoma and Psoriasis, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT04751396: Recruiting study of Melanoma and Psoriasis, sponsored by M.D. Anderson Cancer Center.
NCT04751396 is a study of Melanoma and Psoriasis that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 125 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04751396, a study of Melanoma and Psoriasis, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
Primary Outcome
The scale will be used to assess personal perceptions of 1) uncertainty in choosing among options; 2) modifiable factors contributing to uncertainty, such as feeling uninformed, and 3) feeling that the choice is values-based and likely to be implemented.
Conditions Studied
Interventions
- OTHER Survey Administration
- OTHER Questionnaire Administration
- OTHER Best Practice
- OTHER Educational Intervention
- OTHER Interview
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2027-02-02 |
What NCT04751396 shows while recruiting
NCT04751396 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (82% lower).
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Survey Administration is the first listed.
NCT04751396 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04751396 about?
NCT04751396 is a clinical study titled "Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors". This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of t...
What is the current status of trial NCT04751396?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2022-04-20. Estimated completion is 2027-02-02.
What conditions does trial NCT04751396 study?
This clinical trial studies the following conditions: Melanoma, Psoriasis, Crohn Disease, Psoriatic Arthritis, Inflammatory Bowel Disease.
What interventions are being tested in trial NCT04751396?
The interventions under investigation include: Survey Administration (OTHER), Questionnaire Administration (OTHER), Best Practice (OTHER), Educational Intervention (OTHER), Interview (OTHER).
Who is sponsoring clinical trial NCT04751396?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04751396 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04751396's enrollment target sits among peer trials
125 99th of 266 higher than 168 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI